ACRX Falls on Financing, Creating Opportunity Ahead of Phase III Data
Long Ideas - AcelRx (ACRX) will issue and sell up to 11.5M shares of common stock in the coming weeks, just months ahead of a pivotal period for … Continue Reading
Read nowAuthor Archives: Jake King
CADX Investor/Analyst Day Highlights Strong Ofirmev Growth Trends
Long Ideas - Cadence Pharmaceuticals (NASDAQ:CADX) hosted its Investor/Analyst Day on Thursday morning, and gave a compelling presentation as to why Ofirmev, its primary value driver, should continue … Continue Reading
Read nowCHTP Still Alive; 306b Trial Supports Northera Efficacy & Safety
Quick Picks - Chelsea Therapeutics (CHTP) released preliminary results for its Phase III clinical study, called 306b, which evaluated the efficacy and safety of Northera, the company’s drug … Continue Reading
Read nowImmunoCellular Shares Near Lows Offers a Speculative Oncology Play
Long Ideas - With its balance sheet shored up after a recent stock offering, shares trading just off of their 52-week lows, and interim Phase IIb data expected … Continue Reading
Read nowQCOR Accelerated Dividend Highlights Acthar Growth
Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) announced a per share cash dividend of $0.20 to shareholders of record on December 14, 2012. The payment is accelerated, as the … Continue Reading
Read nowKalydeco Approval in Canada More Important to Patients than to VRTX
Long Ideas - Finally, some Vertex (NASDAQ:VRTX) news unrelated to Hepatitis C. Health Canada, the Canadian medicinal regulatory body, approved Vertex’s Kalydeco (ivacaftor) on Monday for the treatment … Continue Reading
Read nowQCOR Dip Offers Opportunity In Front Of Acthar Script Data
Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) shares fell roughly 8% on Friday following an update from Aetna (NYSE:AET) regarding the insurer’s coverage of QCOR’s lead product, H.P. Acthar … Continue Reading
Read now